Chlamydia trachomatis is the most common sexually-transmitted bacterial pathogen worldwide, causing millions of new infections each year. These infections all too frequently result in serious sequelae in women, including pelvic inflammatory disease, infertility, ectopic pregnancy, and chronic pelvic pain. Although screening programs can reduce the prevalence of chlamydial infections and their complications, primary prevention programs are needed. The use of topical microbicides has been recognized as a productive approach for the prevention of chlamydial infections and STD's in general. Chlamydiae are obligate intracellular bacteria which can only grow within eukaryotic cells. Infectious elementary bodies are found in sexual secretions and are adapted for survival in this environment. The organisms are only extracellular for a brief period of their life cycle, but this extra cellular phase is essential for their transmission from person to person. It is during this brief time that Chlamydia are amenable to killing by topical microbicides. The overall goal of this proposal is to evaluate various topical microbicides for their activity against C. trachomatis. This includes: 1. Providing purified C. trachomatis organisms and performing microbiological and DNA amplification methods of chlamydial detection 2. Performing in vitro minimum cidal concentration (MCC) assays with developed or novel antimicrobial compounds and with excipients to determine their activity against C. trachomatis, and 3. assessing the mode of action of previously identified active compounds on C. trachomatis. The Chlamydia Core will provide purified organisms and highly specialized microbiological detection methods for Chlamydia, materials and techniques available in only a few laboratories in the United States. In addition, the Chlamydia Core will carry out MCC assays with various microbicides against C. trachomatis, utilizing our unique expertise with this highly specialized test. Finally, we will examine the mode of action of several microbicides on this organism, providing the first information about how these microbicides exert their anti-chlamydial effects.

Project Start
1999-09-30
Project End
2000-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Magee-Women's Hospital of Upmc
Department
Type
DUNS #
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Moncla, Bernard J; Guevara, Peter W; Wallace, James A et al. (2012) The inhibitory activity of typified propolis against Enterococcus species. Z Naturforsch C 67:249-56
Wang, Lin; Sassi, Alexandra Beumer; Patton, Dorothy et al. (2012) Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention. Drug Dev Ind Pharm 38:995-1007
Moncla, B J; Pryke, K; Rohan, L C et al. (2012) Testing of viscous anti-HIV microbicides using Lactobacillus. J Microbiol Methods 88:292-6
Moncla, Bernard J; Pryke, Kara; Rohan, Lisa Cencia et al. (2011) Degradation of naturally occurring and engineered antimicrobial peptides by proteases. Adv Biosci Biotechnol 2:404-408
Skinner, M C; Stamm, W E; Lampe, M L (2009) Chlamydia trachomatis laboratory strains versus recent clinical isolates: implications for routine microbicide testing. Antimicrob Agents Chemother 53:1482-9
Patton, Dorothy L; Sweeney, Yvonne T Cosgrove; Paul, Kathleen J (2009) A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 36:350-6
Sassi, Alexandra B; Isaacs, Charles E; Moncla, Bernard J et al. (2008) Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J Pharm Sci 97:3123-39
Moncla, B J; Pryke, K; Isaacs, Charles E (2008) Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (group B streptococcus), Haemophilus ducreyi, and vaginal Lactobacillus by 3-O-octyl-sn-glycerol. Antimicrob Agents Chemother 52:1577-9
Deslouches, Berthony; Gonzalez, Ivan A; DeAlmeida, Dilhari et al. (2007) De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 60:669-72
Patton, D L; Cosgrove Sweeney, Y T; McCarthy, T D et al. (2006) Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 50:1696-700

Showing the most recent 10 out of 42 publications